17,261 trials
Encephalitis · Japanese Encephalitis
Primary: Number of Participants With Seroconversion to Homologous ChimeriVax-JE Virus Strain After a Single Dose of Chimerivax™-JE and Placebo Dose — 194; 191 Participants
Hypertension · End Stage Renal Disease
Primary: Change in Mean Interdialytic 44-hour Ambulatory Systolic Blood Pressure Over a 2 Week Follow-up Period — -1.5; -3.7; -0.4 mm Hg
Male Breast Cancer · Stage II Breast Cancer · Stage IIIA Breast Cancer
Primary: Congestive Heart Failure Rate — 2.9; 2.5 percentage of participants
HIV Infections · Hepatitis C · Liver Disease
Primary: Time-scaled Change in Metavir Liver Fibrosis Score (SCMFS) — 0; 0 Metavir units per one year (52 weeks) — p=0.58
Change in Bone Mineral Density · Change in Bone Marrow Fat Content
Primary: Difference in Percent Change in Bone Mineral Density (BMD) From Baseline to 14 Weeks Between the Rosiglitazone Group and the Placebo Group — -1.3; 0.3 Percent change…
Peyronie's Disease
Primary: Change From Baseline in Penile Curvature — -29.7; -11.0 Percent change from baseline — p=0.001
Major Depressive Disorder · Partner Relational Disorder (V61.10)
Primary: Hamilton Depression Rating Scale (HDRS) — 17.86; 19.0; 5.00; 7.29 Score on HDRS — p=0.056
Myeloma
Primary: Number of Patients Reaching Complete Response (CR) — 4; 1; 4 participants
Gastroesophageal Reflux Disease · Heartburn · Regurgitation
Primary: Number of Participants With a Change in GERD Symptoms Corresponding to at Least Three More Days of Not More Than Mild Symptoms on Average Per Week During Treatment…
Cocaine Dependence · Depressive Symptoms
Primary: Urine Toxicology Screens for the Presence of Cocaine/Cocaine Metabolites — 19.93; 23.38; 17.27 Days to relapse (two consec coc+ urines) — p=0.05
Nicotine Dependence
Primary: Number of Eligible Participants Enrolled Who Completed the Study. — 9; 8 Participants
Non-Small Cell Lung Cancer
Primary: Progression-free Survival — 1.91; 3.52 months
Chronic Lymphocytic Leukemia · Leukemia
Primary: Number of Patients in Overall Response Categories — 3; 1; 10; 30 Participants
Ocular Cicatricial Pemphigoid
Primary: Number of Participants With no Evidence of Further Scarring (Fosters Staging) at 16 Weeks — 0 participants
Dyslipidemia
Primary: Mean Change in Calculated Low Density Lipoprotein Cholesterol — -22.7 mg/dL — p=0.0042